Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Person, Central Contact
ENIGMA-SC, NCT05152563: A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis	Withdrawn	3	280	US	AK002, Lirentelimab, Placebo	Allakos Inc.	Eosinophilic Gastritis, Eosinophilic Duodenitis	01/22	01/22
ATLAS, NCT05155085 / 2022-001625-79: A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis	Terminated	2	131	Europe, US	AK002, Lirentelimab, Placebo	Allakos Inc., Allakos Inc.	Atopic Dermatitis	12/23	04/24
MAVERICK, NCT05528861 / 2022-001847-26: A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria	Terminated	2	127	Europe, US	Lirentelimab (AK002), AK002, Placebo	Allakos Inc., Allakos Inc.	Chronic Spontaneous Urticaria	12/23	04/24